Literature DB >> 19226273

Age and sex as predictors of biochemical activity in acromegaly: analysis of 1485 patients from the German Acromegaly Register.

S Petersenn1, M Buchfelder, B Gerbert, H Franz, H J Quabbe, H M Schulte, M Grussendorf, M Reincke.   

Abstract

OBJECTIVE: We evaluated the German Acromegaly Register for clinical variables associated with the initial biochemical activity of patients with acromegaly.
DESIGN: Retrospective analysis of data in the registry. PATIENTS: A total of 1485 patients with acromegaly (males 45.6%, females 54.4%) were treated in 42 German endocrine centres until November 2005. Linear regression models were used to estimate the influence of various parameters on biochemical activity.
RESULTS: Male patients with acromegaly were significantly younger at the time of diagnosis than female patients (41 vs. 47 years, P < 0.0001) and had significantly higher random GH levels than females (21 vs. 14 ng/ml, P < 0.005) and IGF-1 levels (773 vs. 679 ng/ml, P < 0.0001), respectively. Age at initial presentation turned out to be the most important independent risk factor associated with random GH levels, oral glucose tolerance test-suppressed GH levels, IGF-1 levels, body mass index (BMI), tumour size and prevalence of hypopituitarism. Sex was an independent risk factor for IGF-1 levels, BMI and prevalence of hypopituitarism. Tumour size was an independent risk factor for both GH and IGF-1 levels.
CONCLUSIONS: In summary, initial biochemical activity of acromegaly is influenced by patient's age and to a lesser degree by patient's sex. Male patients are on an average 6 years younger than females.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19226273     DOI: 10.1111/j.1365-2265.2009.03547.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  12 in total

1.  Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort.

Authors:  Caroline Sievers; Dorothee M Baur; Anja Schwanke; Michael Buchfelder; Michael Droste; Klaus Mann; Günter K Stalla
Journal:  Pituitary       Date:  2015-12       Impact factor: 4.107

Review 2.  [Diagnostics and treatment of acromegaly : Necessity for targeted monitoring of comorbidities].

Authors:  S Petersenn; M Christ-Crain; M Droste; R Finke; J Flitsch; I Kreitschmann-Andermahr; A Luger; J Schopohl; G Stalla
Journal:  Internist (Berl)       Date:  2017-11       Impact factor: 0.743

3.  Gender differences and temporal trends over two decades in acromegaly: a single center study in 112 patients.

Authors:  Adriana G Ioachimescu; Talin Handa; Neevi Goswami; Adlai L Pappy; Emir Veledar; Nelson M Oyesiku
Journal:  Endocrine       Date:  2019-11-01       Impact factor: 3.633

4.  Pretreatment serum GH levels and cardio-metabolic comorbidities in acromegaly; analysis of data from Iran Pituitary Tumor Registry.

Authors:  Leila Hedayati Zafarghandi; Mohammad Ebrahim Khamseh; Milad Fooladgar; Shahrzad Mohseni; Mostafa Qorbani; Nahid Hashemi Madani; Mahboobeh Hemmatabadi; MohammadReza Mohajeri-Tehrani; Nooshin Shirzad
Journal:  J Diabetes Metab Disord       Date:  2020-04-05

5.  Using growth hormone levels to detect macroadenoma in patients with acromegaly.

Authors:  Ji Young Park; Jae Hyeon Kim; Sun Wook Kim; Jae Hoon Chung; Yong Ki Min; Myung Shik Lee; Moon Kyu Lee; Kwang Won Kim
Journal:  Endocrinol Metab (Seoul)       Date:  2014-05-27

Review 6.  The risks of overlooking the diagnosis of secreting pituitary adenomas.

Authors:  Thierry Brue; Frederic Castinetti
Journal:  Orphanet J Rare Dis       Date:  2016-10-06       Impact factor: 4.123

7.  Soluble Alpha Klotho in Acromegaly: Comparison With Traditional Markers of Disease Activity.

Authors:  Júnia R O L Schweizer; Katharina Schilbach; Michael Haenelt; Alexandre V Giannetti; Mariana F Bizzi; Beatriz S Soares; Eduardo Paulino; Jochen Schopohl; Sylvère Störmann; Antônio Ribeiro-Oliveira; Martin Bidlingmaier
Journal:  J Clin Endocrinol Metab       Date:  2021-07-13       Impact factor: 5.958

Review 8.  [Acromegaly features in the aging population].

Authors:  Nadia Anoun; Hanan El Ouahabi
Journal:  Pan Afr Med J       Date:  2017-07-04

9.  Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis.

Authors:  Whitney W Woodmansee; Murray B Gordon; Mark E Molitch; Adriana G Ioachimescu; Don W Carver; Beloo Mirakhur; David Cox; Roberto Salvatori
Journal:  Endocrine       Date:  2018-05-16       Impact factor: 3.633

Review 10.  Diabetes Secondary to Acromegaly: Physiopathology, Clinical Features and Effects of Treatment.

Authors:  Francesco Ferraù; Adriana Albani; Alessandro Ciresi; Carla Giordano; Salvatore Cannavò
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-06       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.